在固体瘤中的骨转移性疾病中使用检查点抑制剂
Victoria Wytiaz1, Catherine Van Poznak2
1Division of Hematology Oncology, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI, 48109, USA. wytiazv@umich.edu.
Current osteoporosis reports
|June 9, 2023
概括
免疫检查点抑制剂显示,由于独特的骨微环境,骨转移的结果较差. 需要进一步的研究,以了解和改善对这些疗法在骨癌传播中的反应.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 骨转移研究 骨转移研究
背景情况:
- 骨是固体瘤转移的常见场所.
- 骨在结构完整性,造血和免疫细胞发育中起着至关重要的作用.
- 免疫疗法的使用越来越多,需要了解其对骨转移的影响.
研究的目的:
- 对实体瘤的免疫检查点抑制剂 (ICI) 数据进行审查,重点关注骨转移.
- 突出目前免疫疗法治疗骨转移的挑战.
- 确定骨转移治疗的未来研究领域.
主要方法:
- 对固体瘤中免疫检查点抑制剂的现有数据的审查.
- 专注于报告骨转移结果的研究.
- 分析骨微环境对治疗反应的潜在影响.
主要成果:
- 有限的数据表明,使用ICI治疗的骨转移的结果较差.
- 骨和骨髓的独特免疫微环境可能会导致疗效降低.
- 骨转移与其他转移部位相比,具有独特的挑战.
结论:
- 骨转移可能对ICI的反应不同于其他瘤部位.
- 更深入地了解骨微环境对于提高ICI疗效至关重要.
- 需要专门的研究来优化骨转移的治疗策略.
相关概念视频
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Metastasis
5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
213
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
213


